Changeflow GovPing Pharma & Drug Safety Silver Nanoparticle Treatment for Carious Lesio...
Routine Notice Added Final

Silver Nanoparticle Treatment for Carious Lesions, 3-5 Weeks

Favicon for changeflow.com USPTO Patent Applications - Pharma (A61K)
Published
Detected
Email

Summary

The USPTO published patent application US20260096959A1 filed by R.M CREIGHTON DENTAL PTY LTD for a method of treating carious lesions using silver nanoparticles. The treatment involves applying a first dental solution containing a silver salt followed by a second dental solution containing a reducing agent within less than 10 minutes. The lesion consolidates over 3-5 weeks to form a matte black crust containing nanoparticles. Invented by Graham G. Craig.

What changed

The USPTO published patent application US20260096959A1 disclosing a method for treating carious lesions using silver nanoparticles. The invention involves applying a first dental solution comprising a silver salt to the lesion, followed by a second dental solution comprising a reducing agent within 10 minutes. Over 3-5 weeks, the treated lesion consolidates into a matte black crust containing nanoparticles.

This patent application publication provides public notice of the claimed dental treatment method and its technical specifications. For dental product manufacturers, pharmaceutical companies, and healthcare providers, the publication serves as prior art and may inform research and development activities in dental treatment technologies.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 13, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

Method for Producing Silver Nanoparticles in an Active Carious Lesion

Application US20260096959A1 Kind: A1 Apr 09, 2026

Assignee

R.M CREIGHTON DENTAL PTY LTD

Inventors

Graham G. Craig

Abstract

A method of treating a carious lesion in a tooth which includes a step of applying a first dental solution to the carious lesion of the tooth, applying a second dental solution to the treated carious lesion within less than 10 minutes of the step of applying the first dental solution. The treated carious lesion consolidates forming a crust having a matte black surface and comprising nanoparticles after about 3-5 weeks. The first dental solution comprises an organic or inorganic silver salt and the second dental solution comprises an organic or inorganic reducing agent.

CPC Classifications

A61K 8/19 A61K 8/345 A61Q 11/00 A61K 2800/413 A61K 2800/92

Filing Date

2025-09-30

Application No.

19345469

View original document →

Get daily alerts for USPTO Patent Applications - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
September 30th, 2025
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260096959A1

Who this affects

Applies to
Healthcare providers Manufacturers Medical device makers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent filing Dental treatment
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!